Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Kathy Mikulec"'
Autor:
Nikita Deo, David G. Little, Jad El-Hoss, Aaron Schindeler, Lauren Peacock, Mille Kolind, Kathy Mikulec
Publikováno v:
Journal of Applied Biomedicine. 16:350-357
Tibial pseudarthrosis often features deficient bone formation, excessive bone resorption, and extensive pathological fibrosis, particularly in individuals with Neurofibromatosis type I (NF1). It was hypothesized that overactive NF1-Ras-JNK signalling
Autor:
Kathy Mikulec, Lauren Peacock, Emily R Vasiljevski, David G. Little, Aaron Schindeler, Matthew A. Summers
Publikováno v:
Molecular Genetics and Metabolism. 123:518-525
Neurofibromatosis Type 1 (NF1) is a common autosomal dominant genetic disorder While NF1 is primarily associated with predisposition for tumor formation, muscle weakness has emerged as having a significant impact on quality of life. NF1 inactivation
Autor:
Sandra T. Cooper, David A. Stevenson, Kate G. R. Quinlan, Ute Roessner, Aaron Schindeler, Thusitha T.W. Rupasinghe, David G. Little, Emily R Vasiljevski, Kathy Mikulec, Matthew A. Summers, Lauren Peacock, Frances J. Evesson
Publikováno v:
Human Molecular Genetics. 27:577-588
Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder with complex symptomology. In addition to a predisposition to tumors, children with NF1 can present with reduced muscle mass, global muscle weakness, and impaired motor skills,
Autor:
Tegan L. Cheng, Patrick P.L. Tam, Lauren Peacock, Paul A. Baldock, Michelle M. McDonald, Peter I. Croucher, Alyson Morse, Aaron Schindeler, Justin D. Bobyn, Kathy Mikulec, David G. Little, Lucinda R. Lee
Publikováno v:
Calcified Tissue International. 102:105-116
Wnt antagonist Dkk1 is a negative regulator of bone formation and Dkk1 +/− heterozygous mice display a high bone mass phenotype. Complete loss of Dkk1 function disrupts embryonic head development. Homozygous Dkk1 −/− mice that were heterozygous
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lauren Peacock, David G. Little, Michaela Kneissel, Kathy Mikulec, Craig F Munns, Ina Kramer, Tegan L. Cheng, Aaron Schindeler
Publikováno v:
Bone. 101:96-103
In this study, we examined the therapeutic potential of anti-Sclerostin Antibody (Scl-Ab) and bisphosphonate treatments for the bone fragility disorder Osteogenesis Imperfecta (OI). Mice with the Amish OI mutation (Col1a2 G610C mice) and control wild
Publikováno v:
The International Journal of Developmental Biology. 61:531-536
Neurofibromatosis Type 1 (NF1) is an autosomal dominant genetic disorder that results in a variety of characteristic manifestations. Prior studies have shown reduced muscle size and global skeletal muscle weakness in children with NF1. This associate
Autor:
Brya G. Matthews, Aaron Schindeler, Kathy Mikulec, Alastair Aiken, Mille Kolind, David G. Little, Ivo Kalajzic, Justin D. Bobyn
Publikováno v:
Bone. 81:53-59
To better understand the relative contributions of mesenchymal and endothelial progenitor cells to rhBMP-2 induced bone formation, we examined the distribution of lineage-labeled cells in Tie2-Cre:Ai9 and αSMA-creERT2:Col2.3-GFP:Ai9 reporter mice. E
Autor:
Tegan L. Cheng, Aaron Schindeler, David G. Little, Rebecca J. Mills, Carl Genberg, Paul B. Savage, Kathy Mikulec, Lauren Peacock, David Isaacs
Publikováno v:
Clinical orthopaedics and related research. 476(6)
BACKGROUND: Infection of open fractures remains a significant cause of morbidity and mortality to patients worldwide. Early administration of prophylactic antibiotics is known to improve outcomes; however, increasing concern regarding antimicrobial r
Autor:
Kathy Mikulec, Min Liu, Aaron Schindeler, Hua Zhu Ke, Nicole Y C Yu, Oliver Birke, Michelle M. McDonald, Alyson Morse, David G. Little, Lauren Peacock
Publikováno v:
Journal of Orthopaedic Research.
Neutralizing monoclonal sclerostin antibodies are effective in promoting bone formation at a systemic level and in orthopedic scenarios including closed fracture repair. In this study we examined the effects of sclerostin antibody (Scl-Ab) treatment